Compare Lowe`s Companies Inc (LOW) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lowe`s Companies Inc vs Summit Therapeutics Inc — how do they compare? Lowe`s Companies Inc trades at $186 (market cap $105.96B), while Summit Therapeutics Inc trades at $17.59 (market cap $13.71B). The key difference: Lowe`s Companies Inc is far larger — about 7.7× Summit Therapeutics Inc's market cap, and Lowe`s Companies Inc pays a 2.65% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Lowe`s Companies Inc for 98 Days and Summit Therapeutics Inc for 16 Days on average.
| LOW | SMMT | |
|---|---|---|
Market Cap | $105.96B | $13.71B |
Volume | 4,039,547 | 6,173,057 |
Sector | Consumer Cyclical | Health |
52-Week High | $287.39 | $26.38 |
52-Week Low | $179.50 | $12.43 |
Typical Hold Time | 98 Days | 16 Days |
Enterprise Value | $144.81B | $13.04B |
Dividend Yield | 2.65% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lowe's (LOW) trades at $188.85, up 4.03% with strong earnings beats in recent quarters. The stock shows bearish technical signals but maintains solid fundamentals with 7.35% net margins and reasonable valuation at 15.96 P/E. Recent drone delivery innovation with DoorDash and Alphabet demonstrates operational adaptation amid challenging home improvement market conditions.
Outlook remains cautious with housing market headwinds, though analyst consensus targets $244.09 (29% upside). Key risks include interest rate sensitivity and competitive pressure from Home Depot. The company's Dividend King status and consistent cash flow generation provide stability for long-term investors.
Summit Therapeutics (SMMT) trades at $17.17, down 4.35% on the day, amid mixed technical signals with a bullish moving average trend but neutral oscillators. The company reported no revenue in 2025 and a net loss of $1.08 billion, with negative ROE and ROA, yet maintains a high P/B ratio of 21.76. Recent positive sentiment is driven by a $2 billion strategic investment from AstraZeneca and expanded clinical collaborations for its lead drug ivonescimab, as reported by Reuters and Business Wire on September 28-29, 2026.
The outlook hinges on clinical success; upside exists if ivonescimab trials meet endpoints, supported by strong analyst consensus (65% buy rating) and a $29.33 price target. Key risks include cash burn from negative operating cash flow, drug development failures, and reliance on partnership outcomes, posing significant volatility for investors despite institutional interest.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lowe`s Companies Inc
Lowe's is the second-largest home improvement retailer in the world, operating 1,969 stores and servicing around 230 dealer-owned stores throughout the United States and Canada. The firm's stores offer products and services for home decorating, maintenance, repair, and remodeling, with maintenance and repair accounting for two thirds of products sold. Lowe's targets retail do-it-yourself (around 75% of sales) and do-it-for-me customers as well as commercial and professional business clients (around 25% of sales). We estimate Lowe's captures a low-double-digit share of the domestic home improvement market, based on U.S. Census data and management's estimates for market size.
Read more on LOW →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
